ArticleFrontiers in aging neuroscience2026
Hydrogen gas and olfactory dysfunction in Alzheimer's disease: the Hydrogen-Olfactory-Limbic hypothesis.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory dysfunction is increasingly recognized as an early clinical feature of Alzheimer's disease (AD), often preceding measurable cognitive impairment and associated with subsequent cognitive decline. Despite this relatively consistent clinical association, the anatomical, cellular, and physiological substrates underlying olfactory dysfunction in AD remain poorly understood. Post-mortem human studies have identified amyloid-β (Aβ) and tau pathology in olfactory structures, including the olfactory epithelium and anterior olfactory nucleus. However, the available anatomical evidence remains limited, and the presence of these pathological proteins does not establish that they cause olfactory dysfunction. Likewise, it remains uncertain whether early olfactory impairment reflects peripheral sensory dysfunction, neuronal loss, synaptic or circuit abnormalities, altered higher-order olfactory processing, disruption of olfactory-limbic networks, or a combination of these processes. Although the olfactory epithelium possesses lifelong regenerative capacity, whether this capacity is altered during AD progression remains unresolved. Molecular hydrogen (H₂) has demonstrated antioxidant, anti-inflammatory, mitochondrial-modulatory, and cytoprotective effects in diverse experimental systems. However, direct evidence that hydrogen modifies AD-associated olfactory dysfunction is currently lacking. In this Perspective, we propose the Hydrogen-Olfactory-Limbic hypothesis as an experimentally testable framework rather than an established therapeutic mechanism. We suggest that molecular hydrogen can serve as an experimental intervention to determine whether modulating oxidative, inflammatory, and metabolic processes affects olfactory function and olfactory-limbic circuit physiology during AD progression. This framework integrates behavioral, anatomical, molecular, electrophysiological, regenerative, and connectivity measurements to address two fundamental questions: what causes early olfactory dysfunction in AD, and can molecular hydrogen modify biologically relevant processes associated with this phenotype?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.